CDMO Dossier

GLOSSARY · PLAIN DEFINITIONS

CDMO terms: drug substance, capacity, and qualification

Plain-language definitions for early biologics manufacturing screens. Source announcement and retrieval dates appear centrally on Sources & dates.

CDMO (Contract Development and Manufacturing Organization)
A third-party company hired by a biopharma sponsor to develop manufacturing processes, run analytical testing, and produce clinical or commercial drug material under cGMP rules.
Drug substance (DS) vs. drug product (DP)
Drug substance is the unformulated active biologic molecule produced in upstream and downstream manufacturing runs. Drug product is the finished dosage form filled into vials or syringes for patient use.
Mammalian expression
Using mammalian host cell lines to express complex therapeutic proteins such as monoclonal antibodies. See Protein scope for reviewed site wording.
Disclosed site capacity vs. bookable capacity
Disclosed capacity is the nominal size or total of installed bioreactors (in L or kL) published by a vendor. Bookable capacity is open suite schedule available for a new sponsor campaign. How to read capacity figures.
Single-use vs. stainless steel bioreactors
Single-use bioreactors run cell culture inside disposable sterile polymer bags, whereas stainless steel bioreactors use fixed clean-in-place steel vessels. Reviewed sites publish capacities in their own native scales and configurations; see Capacity.
Bioconjugate / ADC (Antibody-Drug Conjugate)
A targeted biologic linking an antibody to a payload/linker component, involving conjugation manufacturing steps distinct from standalone unconjugated antibody drug substance.

← Return to the site comparison